nach oben

Digestive Diseases and Sciences

Erschienen in:

01.10.2007 | Original Paper

Acid-Suppressive Effects of Various Regimens of Omeprazole in Helicobacter pylori-Negative CYP2C19 Homozygous Extensive Metabolizers: Which Regimen Has the Strongest Effect?

verfasst von: Tomohiko Shimatani, Tomoko Kuroiwa, Mutsuko Moriwaki, Jing Xu, Susumu Tazuma, Masaki Inoue

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

To achieve more potent and long-lasting acid suppression, omeprazole was administered for 7 days in 5 regimens: 10, 20, and 40 mg once daily (od), and 10 and 20 mg twice daily (bid), in 7 healthy Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers, and intragastric pH was continuously measured. The median intragastric pH and percent time pH > 4.0 for 24 hours increased dose dependently with 10, 20, and 40 mg od. Ten and 20 mg bid wre comparable to 20 and 40 mg od, respectively. Concerning percent time pH > 4.0 in the nighttime (20:00–8:00 hours), 20 mg bid was significantly superior to 40 mg od (P < .05). In 4 of the 5 regimens, all 7 subjects had nocturnal acid breakthrough, whereas with 20 mg bid it occurred in only 3. We concluded that, considering nighttime acid suppression, omeprazole 20 mg bid had the strongest effect.

Sachs G, Wallmark B (1989) The gastric H⁺,K⁺-ATPase: the site of action of omeprazole. Scand J Gastroenterol (Suppl) 166:3–11

Sachs G, Shin JM, Briving C, Wallmark B, Hersey S (1995) The pharmacology of the gastric acid pump: the H⁺,K⁺ ATPase. Annu Rev Pharmacol Toxicol 35:277–305PubMedCrossRef

Bate CM, Keeling PW, O’Morain C, Wilkinson SP, Foster DN, Mountford RA, Temperley JM, Harvey RF, Thompson DG, Davis M, Forgacs IC, Bassett KS, Richardson PDI (1990) Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 31:968–972PubMed

Porro GB, Pace F, Peracchia A, Bonavina L, Vigneri S, Scialabba A, Franceschi M (1992) Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. J Clin Gastroenterol 15:192–198CrossRef

Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, Solcia E, Shearman DJ (1994) Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 35:590–598PubMed

Hallerback B, Unge P, Carling L, Edwin B, Glise H, Havu N, Lyrenas E, Lundberg K (1994) Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 107:1305–1311PubMed

Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, Di Mario F, Battaglia G, Mela GS, Pilotto A, Plebani M, Davi G (1995) A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333:1106–1110PubMedCrossRef

Robertson D, Aldersley M, Shepherd H, Smith CL (1987) Patterns of acid reflux in complicated oesophagitis. Gut 28:1484–1488PubMed

Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A, Rumi MA, Watanabe M, Kinoshita Y (2001) Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16:1191–1196PubMedCrossRef

10.

Katz PO (2005) Review article: putting immediate-release proton-pump inhibitors into clinical practice—improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. Aliment Pharmacol Ther 22(Suppl 3):31–38PubMedCrossRef

11.

Peghini PL, Katz PO, Bracy NA, Castell DO (1998) Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763–767PubMedCrossRef

12.

Peghini PL, Katz PO, Castell DO (1998) Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 115:1335–1339PubMedCrossRef

13.

Ohara S, Kimpara T, Sekine H, Moriyama S, Kato K, Nakayama Y, Saito N, Sugiyama K, Asaki S, Toyota T (1995) Comparison of acid-inhibitory effect of omeprazole in before-breakfast dosing and after-breakfast dosing [in Japanese]. Jpn Pharmacol Ther 23:879–885

14.

Kuo B, Castell DO (1996) Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 91:1532–1538PubMed

15.

Hatlebakk JG, Katz PO, Kuo B, Castell DO (1998) Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 12:1235–1240PubMedCrossRef

16.

Orr WC, Harnish MJ (2003) The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 17:1553–1558PubMedCrossRef

17.

Wilder-Smith C, Halter F, Ernst T, Gennoni M, Zeyen B, Varga L, Roehmel JJ, Merki HS (1990) Loss of acid suppression during dosing with H2-receptor antagonists. Aliment Pharmacol Ther 4(Suppl 1):15–27PubMed

18.

Nwokolo CU, Smith JT, Gavey C, Sawyerr A, Pounder RE (1990) Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 4(Suppl 1):29–45PubMed

19.

Smith JT, Gavey C, Nwokolo CU, Pounder RE (1990) Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. Aliment Pharmacol Ther 4(Suppl 1):47–63PubMed

20.

Rogers MJ, Holmfield JH, Primrose JN, Johnston D (1990) The effects of 15 days of dosing with placebo, sufotidine 600 mg nocte or sufotidine 600 mg twice daily upon 24-hour intragastric acidity and 24-hour plasma gastrin. Aliment Pharmacol Ther 4(Suppl 1):65–74PubMed

21.

Nwokolo CU, Sawyerr A, Smith JT, Pounder RE (1990) Intravenous pentagastrin can induce the illusion of ‘tolerance’ to a single dose of an H2-blocker in man. Aliment Pharmacol Ther 4(Suppl 1):75–83PubMed

22.

Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS (1990) Tolerance to oral H2-receptor antagonists. Dig Dis Sci 35:976–983PubMedCrossRef

23.

Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, Ishizaki T (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552–561PubMedCrossRef

24.

Shimatani T, Inoue M, Kuroiwa T, Horikawa Y, Mieno H, Nakamura M (2003) Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist. Aliment Pharmacol Ther 18:1149–1157PubMedCrossRef

25.

Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, Sato Y, Kajimura M, Futami H, Takayanagi S, Yamada M, Ohashi K, Ishizaki T, Hanai H (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453–460PubMedCrossRef

26.

Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S, Noguchi K, Hamada S, Noguchi M, Shimosegawa T; Study Group of GERD (2003) The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 17:965–973PubMedCrossRef

27.

Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69:158–168PubMedCrossRef

28.

Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, Okumura K, Kasuga M (2003) Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 15:27–33PubMedCrossRef

29.

de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598PubMed

30.

de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422PubMed

31.

Kubota T, Chiba K, Ishizaki T (1996) Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661–666PubMedCrossRef

32.

Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L (1983) Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man. Gut 24:270–276PubMed

33.

Naesdal J, Bodemar G, Walan A (1984) Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol 19:916–922PubMed

34.

Howden CW, Forrest JA, Reid JL (1984) Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 25:707–710PubMed

35.

Olbe L, Cederberg C, Lind T, Olausson M (1989) Effect of omeprazole on gastric acid secretion and plasma gastrin. J Gastroenterol Hepatol 4(Suppl 2):19–25PubMed

36.

Nakashima M, Kanamaru M, Hashimoto H, Takiguchi Y, Mizuno A, Kajiho H, Oka T, Matsuda Y (1988) Phase I study of omeprazole-single-dose and multiple-dose studies [in Japanese]. Jpn J Clin Pharmacol Ther 19:667–679

37.

Andersson T, Andren K, Cederberg C, Heggelund A, Lundborg P, Rohss K (1990) Bioavailability of omeprazole as enteric coated (EC) granules in conjunction with food on the first and seven days of treatment. Drug Invest 2:184–188

38.

Howden CW (1991) Clinical pharmacology of omeprazole. Clin Pharmacokinet 20:38–49PubMed

39.

Stedman CA, Barclay ML (2000) Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963–978PubMedCrossRef

Titel: Acid-Suppressive Effects of Various Regimens of Omeprazole in Helicobacter pylori-Negative CYP2C19 Homozygous Extensive Metabolizers: Which Regimen Has the Strongest Effect?
verfasst von: Tomohiko Shimatani
Tomoko Kuroiwa
Mutsuko Moriwaki
Jing Xu
Susumu Tazuma
Masaki Inoue
Publikationsdatum: 01.10.2007
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 10/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-006-9643-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2007

Preventing Relapse of Major Depression During Interferon-α Therapy for Hepatitis C—A Pilot Study

The Influence of Hemorrhagic Shock on Rat Liver Regeneration after Partial Hepatectomy: Serum Aminotranspherases, Mitochondrial Function, and Hepatocellular Replication Studies

Intestinal Gas Retention in Patients with Idiopathic Slow-Transit Constipation

Correlation Between Gastrointestinal Symptoms and Gastric Leptin and Ghrelin Expression in Patients with Gastritis

Drug-Induced Liver Injury: Review Article